Purpose: Melanoma-associated germ-line mutations affecting the tumor suppre
ssor and cyclin-dependent kinase (CDK) inhibitor, CDKN2A/p16(INK4a) have be
en identified in > 100 melanoma-prone families. To predict the melanoma ris
k for carriers of specific mutations, it is useful to test the function of
the mutant proteins in biochemical assays; however, it is unclear how well
these results correlate with their cellular effects. We examined the relati
onship between loss of CDK binding by mutant proteins and various measures
of cellular growth in melanoma cells.
Experimental Design: The cellular activities of four melanoma-associated pl
6(INK4a) mutations (Arg24Pro, Ala36Pro, Met53Ile, and Val126Asp) were compa
red by use of inducible expression in stably transfected melanoma cells, de
ficient in expression of the endogenous protein, and compared with their ab
ility to bind CDK4.
Results: The cell cycle-inhibitory activity of all of the mutants was profo
undly reduced, and partially retained capacity for CDK4 binding in function
al assays did not correlate with significant preservation of cell cycle-reg
ulatory function.
Conclusion: Testing of p16(INK4a) interactions with CDKs in protein-binding
assays is an unreliable predictor of mutant p16(INK4a) function in cells.
In addition to exhibiting reduced stability, these mutant proteins may also
be defective in interaction with cellular targets other than CDKs.